Although few patients with ovarian cancer were included in the phase I clinical trial of a drug targeting HGF/c-MET, the phase II clinical trial of rilotumumab in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma demonstrated a significant effect [100]. This evidence concerns the gene MET and ovarian carcinoma.